Advice
in the absence of a submission from the holder of the marketing authorisation:
clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) is not recommended for use within NHS Scotland.
Indication under review: Symptomatic treatment of focal spasticity of lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice135KB (PDF)
Medicine details
- Medicine name:
- clostridium botulinum type A toxin-haemagglutinin complex 300 and 500 units (Dysport)
- SMC ID:
- 1321/18
- Indication:
- Symptomatic treatment of focal spasticity of lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury.
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 March 2018